-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Equities Analysts Set Expectations for Antibe Therapeutics Inc.'s FY2023 Earnings (OTCMKTS:ATBPF)
Equities Analysts Set Expectations for Antibe Therapeutics Inc.'s FY2023 Earnings (OTCMKTS:ATBPF)
Antibe Therapeutics Inc. (OTCMKTS:ATBPF – Get Rating) – Investment analysts at Zacks Small Cap increased their FY2023 EPS estimates for Antibe Therapeutics in a research note issued to investors on Wednesday, September 7th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings per share of ($0.35) for the year, up from their previous estimate of ($0.36). The consensus estimate for Antibe Therapeutics' current full-year earnings is ($0.31) per share.
Get Antibe Therapeutics alerts:Separately, Brookline Capital Management reaffirmed a "buy" rating on shares of Antibe Therapeutics in a report on Thursday, June 30th.
Antibe Therapeutics Price Performance
Antibe Therapeutics stock opened at $0.49 on Monday. Antibe Therapeutics has a 1-year low of $0.42 and a 1-year high of $1.07. The company's 50-day moving average is $0.48 and its 200 day moving average is $0.53.Antibe Therapeutics Company Profile
(Get Rating)
Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.
Recommended Stories
- Get a free copy of the StockNews.com research report on Antibe Therapeutics (ATBPF)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Antibe Therapeutics Inc. (OTCMKTS:ATBPF – Get Rating) – Investment analysts at Zacks Small Cap increased their FY2023 EPS estimates for Antibe Therapeutics in a research note issued to investors on Wednesday, September 7th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings per share of ($0.35) for the year, up from their previous estimate of ($0.36). The consensus estimate for Antibe Therapeutics' current full-year earnings is ($0.31) per share.
安提贝治疗公司(OTCMKTS：ATBPF-GET评级)-在9月7日星期三发布给投资者的一份研究报告中，Zack Small Cap的投资分析师上调了他们对安提贝治疗公司2023财年每股收益的估计。Zack Small Cap分析师D.Bautz现在预计，该公司今年的每股收益将为0.35美元，高于此前预测的0.36美元。对安提贝治疗公司目前全年收益的普遍估计为每股0.31美元。
Separately, Brookline Capital Management reaffirmed a "buy" rating on shares of Antibe Therapeutics in a report on Thursday, June 30th.
另外，Brookline资本管理公司在6月30日星期四的一份报告中重申了对安替比治疗公司股票的“买入”评级。
Antibe Therapeutics Price Performance
安替比治疗药物性价比
Antibe Therapeutics Company Profile
安提贝治疗公司简介
(Get Rating)
(获取评级)
Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.
安提贝治疗公司是一家生物技术公司，致力于在加拿大、欧洲、美国和国际上开发疼痛、炎症和再生医学领域的新型疗法和医疗设备。该公司的药物旨在防止非类固醇抗炎药造成的胃肠道损伤和出血。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Antibe Therapeutics (ATBPF)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免费获取StockNews.com关于抗菌药物治疗的研究报告(ATBPF)
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别，但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
- 这是对第三季度收益报告季节的预期
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《安提贝治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对安替比治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧